Case of Myocarditis After Chimeric Antigen Receptor T Cells With Intracardiac Lymphoma

Dae Hyun Lee; Michael Jain; Aleksandr Lazaryan; Frederick L Locke; Daniel Jeong; Mohammed Alomar

doi:10.1016/j.jaccas.2022.09.004

Case of Myocarditis After Chimeric Antigen Receptor T Cells With Intracardiac Lymphoma

JACC Case Rep. 2022 Nov 3:8:101634. doi: 10.1016/j.jaccas.2022.09.004. eCollection 2023 Feb 15.

Authors

Dae Hyun Lee^{1

2}, Michael Jain³, Aleksandr Lazaryan³, Frederick L Locke³, Daniel Jeong⁴, Mohammed Alomar^{1

2}

Affiliations

¹ Division of Cardiovascular Medicine, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
² Department of Cardio-Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
³ Department of Bone and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, Florida.
⁴ Department of Radiology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.

Abstract

Chimeric antigen receptor T cells (CAR-T) therapy is a novel therapeutic approach that modifies T cells to attack cancer cells, including lymphoma. We present a case of large B cell lymphoma with intracardiac involvement treated with CAR-T in a patient who later experienced myocarditis after CAR-T therapy. (Level of Difficulty: Advanced.).

Keywords: CAR-T, chimeric antigen receptor T cell; CMR, cardiac magnetic resonance; FDG PET-CT, F-18 fluorodeoxyglucose positron emission tomography/computed tomography; chimeric antigen receptor T cell; cytokine release syndrome; intracardiac lymphoma; myocarditis.